文献速递妇科

ROMANHY试验长期肿瘤学结局:早期子宫内膜癌微创手术中宫内举宫器的影响

Long-term Oncological Outcomes of the ROMANHY Trial: Impact of Intrauterine Manipulator During Minimally Invasive Surgery for Early-Stage Endometrial Cancer.
PubMed 文献 · J Minim Invasive Gynecol · 2026-08-12

ROMANHY试验是一项多中心随机对照研究,纳入154例疑似FIGO 2009 I期、子宫内膜样低级别(G1-G2)子宫内膜癌患者,随机分为使用或不使用Clermont-Ferrand宫内举宫器行微创子宫切除术。中位随访96.8个月(95% CI 94.3-98.5)后,两组在淋巴血管间隙浸润(LVSI)、无病生存、总生存及癌症特异性生存方面均无差异;多变量分析仅FIGO分期独立预测无病生存,举宫器使用与否无关。

要点

  • 中位随访96.8个月,举宫器组与未使用组肿瘤学结局无显著差异。
  • 多变量分析仅FIGO分期独立预测无病生存(HR 6.93/12.53)。
  • 在低危早期子宫内膜癌微创手术中,举宫器未增加不良肿瘤学风险。

核心结论

  • 在疑似早期低级别子宫内膜癌的微创分期手术中,使用宫内举宫器与长期不良肿瘤学结局无关。

研究设计与样本

  • 多中心随机对照试验的长期随访分析,共纳入154例患者,来自意大利5个三级转诊中心。

主要发现

  • 中位随访96.8个月(95% CI 94.3-98.5)期间,共发生16例复发和9例死亡,其中5例为癌症特异性死亡。
  • 两组间LVSI(p = .501)、无病生存(p = .910)、总生存(p = .837)和癌症特异性生存(p = .566)均无显著差异。
  • 多变量分析中,仅FIGO分期独立预测无病生存(FIGO 2009 HR 6.93,p = .001;FIGO 2023 HR 12.53,p < .001),使用举宫器无显著关联(HR 1.08,p = .876)。

临床怎么用

  • 对于疑似早期低级别子宫内膜癌患者,微创分期手术中使用宫内举宫器不增加长期复发或死亡风险。

局限性

  • 研究人群为经过选择的低危患者(FIGO 2009 I期、G1-G2子宫内膜样癌),结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: The ROMANHY trial (NCT02762214) was a multicenter randomized study originally designed to assess the impact of intrauterine manipulator (IUM) use on lymphovascular space invasion (LVSI) during minimally invasive staging surgery for presumed early-stage endometrial cancer (EC). This extended follow-up analysis evaluated whether IUM use was associated with long-term oncologic outcomes. DESIGN: Multicenter randomized controlled trial with long-term follow-up. SETTING: Five tertiary referral centers in Italy. PATIENTS: A total of 154 patients with presumed FIGO 2009 stage I, endometrioid low-grade (G1-G2) EC undergoing minimally invasive surgery between October 2015 and December 2017. INTERVENTIONS: Patients were randomized 1:1 to minimally invasive hysterectomy performed with or without a Clermont-Ferrand intrauterine manipulator. MEASUREMENTS AND MAIN RESULTS: After a median follow-up of 96.8 months (95% CI 94.3-98.5), 16 recurrences and 9 deaths occurred, including 5 cancer-specific deaths. No differences were observed between groups in LVSI (p = .501), disease-free survival (p = .910), overall survival (p = .837), or cancer-specific survival (p = .566). On multivariable analysis, only FIGO stage independently predicted disease-free survival (HR2009 6.93, p = .001; HR2023 12.53, p <.001), whereas IUM use did not (HR 1.08, p = .876). CONCLUSION: In this randomized trial, IUM use during minimally invasive staging for presumed early-stage low-grade EC was not associated with worse oncologic outcomes after extended follow-up (median 96.8 months) in a selected low-risk population. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02762214, registered May 2, 2016. https://clinicaltrials.gov/study/NCT02762214.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Perrone E, Parisi G, Pasciuto T, et al. Long-term Oncological Outcomes of the ROMANHY Trial: Impact of Intrauterine Manipulator During Minimally Invasive Surgery for Early-Stage Endometrial Cancer. J Minim Invasive Gynecol. 2026. PMID: 42586310. doi:10.1016/j.jmig.2026.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。